A Long-term Follow-up Study of Sotatercept for PAH Treatment

An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

18+

Learn more

A Phase 3 Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk of Mortality

18-75

Learn more

A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients

18+

Learn more

A Phase 3 Study of Sotatercept for the Treatment of PAH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH

18-18

Learn more

Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON-OLE)

An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

40-99

Learn more

Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

40+

Learn more

ELGAN 3

Environment, Epigenetics, Neurodevelopment and Health of Extremely Preterm Children

15+

Learn more

The Connection study

A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis

No minimum age

Learn more

Placental function in early pregnancy

Placental function in early pregnancy

18-45

Learn more

MAMMA Study

Maternal Metabolic Mediators of infant Adiposity (MaMMA)

18-45

Learn more